Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials

Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and morta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2016-03, Vol.34 (13), p.1496-1503
Hauptverfasser:	Diao, Wen-qi, Shen, Ning, Yu, Pan-xi, Liu, Bei-bei, He, Bei
Format:	Artikel
Sprache:	eng
Schlagworte:	23-Valent pneumococcal polysaccharide vaccine Adult Aged Aged, 80 and over Allergy and Immunology Chronic obstructive pulmonary disease Community-Acquired Infections - prevention & control Community-acquired pneumonia Efficacy Health Services Needs and Demand Humans Immunization Immunocompetent Meta-analysis Middle Aged Mortality Pneumococcal Vaccines - therapeutic use Pneumonia Pneumonia, Pneumococcal - prevention & control Randomized Controlled Trials as Topic Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and mortality from pneumonia. • It does not prevent all-cause mortality.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2016.02.023